FDA approves Eli Lilly's oral SERD Inluriyo combo for second-line metastatic breast cancer

The FDA has given approval to a new combination therapy from Eli Lilly that includes its oral selective estrogen receptor degrader, Inluriyo, for patients with metastatic breast cancer who have progressed after prior treatment.

The regimen is intended as a second-line option, expanding treatment choices for individuals whose disease has advanced despite earlier therapies.

The approval follows Lilly’s ongoing development of oral SERD agents, which aim to improve convenience and efficacy compared with injectable alternatives.

The decision may influence prescribing patterns and could affect market dynamics for breast cancer therapies.